Kenvue Announces Closing of Initial Public Offering
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments.
- Kenvue Inc. (NYSE: KVUE) (“Kenvue”) the world’s largest pure-play consumer health company by revenue, today announced the closing of its initial public offering (“IPO”) of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters’ full exercise of their option to purchase 25,921,884 shares to cover over-allotments.
- Shares of Kenvue’s common stock began trading on the New York Stock Exchange under the symbol “KVUE” on May 4, 2023.
- As of the closing of the IPO, Johnson & Johnson (NYSE: JNJ) owns approximately 89.6% of the total outstanding shares of Kenvue common stock.
- Johnson & Johnson has publicly stated that it has an intention to dispose of its majority stake in Kenvue common stock in 2023, subject to market conditions.